Strong Earnings Boost Profit

Aster DM Healthcare announced a strong finish to fiscal year 2026, with fourth-quarter net profit soaring 77.4% year-on-year to ₹140.2 crore from ₹79 crore. Revenue increased a healthy 18.2% to ₹1,182.4 crore. The results were boosted by a 21.1% rise in EBITDA to ₹232.6 crore, lifting the EBITDA margin to 20% from 19% a year ago. The core hospital business reported strong operational EBITDA margins of 23.1% (excluding Kasaragod). On a proforma basis, including Quality Care India Ltd., revenue reached ₹2,361 crore, up 18%, with operating EBITDA growing 25% to ₹517 crore and margins at 21.9%. However, the company's trailing twelve-month P/E ratio, estimated between 94x and 120x, is significantly higher than peers like Apollo Hospitals (60-77x), Fortis Healthcare (65-74x), and Max Healthcare (67-70x). This suggests the market is pricing in substantial future growth and merger benefits that are not yet fully reflected. The stock closed up 0.79% at ₹705.00 following the announcement.

Operations and Key Growth Drivers

Growth was fueled by a 15% rise in total patient volumes (outpatient up 15%, inpatient up 7%) and a 9% increase in average inpatient revenue per patient to ₹1,25,234. Medical Value Travel (MVT) revenue grew 41%, notably strong with a 51% surge in Kerala. Cardiac and oncology services also showed robust growth. Aster Labs was a standout, with revenue up 18% and operating EBITDA jumping 181% to a 14.7% margin, up from 6.2%. Yet, the core hospital business saw a slight dip in operating EBITDA margin to 23.1% from 24.3% a year ago (excluding Kasaragod), pointing to a balance between pursuing growth and maintaining margins.

Merger Progress and Synergies

Progress on the merger with Quality Care India Ltd. continues. The company has completed a preferential allotment of about 3.6% stake to Blackstone and TPG. Key approvals from the Competition Commission of India (CCI), stock exchanges, shareholders, and creditors have been obtained. The merger awaits a final regulatory order from the National Company Law Tribunal (NCLT) and is expected to close in the first quarter of fiscal year 2027. The combined entity is set to be one of India's largest hospital groups, with 38 hospitals and over 10,300 beds, and is anticipated to deliver 10-15% in near-term EBITDA synergies through increased scale and operational improvements.

Valuation Concerns Amid Growth

The company's clear profit growth stands against a high valuation that requires careful review. Its substantial P/E ratio indicates high investor expectations, potentially leading to stock price swings if growth slows or the merger encounters unexpected problems. The slight decrease in core hospital operating EBITDA margins, despite overall company gains, questions the long-term profitability of its established divisions. The pending NCLT order remains a potential regulatory hurdle that could delay the merger. While most analysts rate the stock positively with price targets between ₹710-₹775, some warn about possible regulatory issues and increased competition in the Indian healthcare market. This mixed outlook means investors should watch its high valuation closely.

Positive Healthcare Sector Outlook

Aster DM Healthcare operates in a healthcare sector with strong growth drivers. The Indian healthcare industry is expected to grow steadily due to rising healthcare spending, an aging population, increasing chronic diseases, and greater health awareness. Government support for healthcare and medical tourism is also expected to boost the sector. ICRA has rated the Indian hospital industry outlook as 'Positive' for FY2026, forecasting sustained operational performance with good occupancy rates, revenue per occupied bed growth, and operating profit margins between 22-24%. Healthcare is also a major job creator, expected to lead hiring in early 2026. Aster's plans to add over 2,100 beds by FY27 fit this positive industry trend. Successfully integrating Quality Care India Ltd. is set to greatly expand Aster's operations, which could support its current valuation if planned growth and synergies are achieved.